Stock Events

Stock Events

Inventiva 

€4.11
98
-€0.02-0.48% Friday 15:30

Statistics

Day High
4.08
Day Low
3.94
52W High
4.75
52W Low
2.99
Volume
25,177
Avg. Volume
-
Mkt Cap
969.74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27SepExpected
Q4 2024
Q2 2025
Q4 2025
Next
-1.93
-1.41
-0.88
-0.36
Expected EPS
-0.36381760295599996
Actual EPS
N/A

Financials

-7,899.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.48MRevenue
-354.14MNet Income

Analyst Ratings

9.86Average Price Target
The highest estimate is 9.86.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6IV.XETRA. It's not an investment recommendation.
NVIDIA
11
NVDA
TotalEnergies
9
TTE.PA
Microsoft
8
MSFT
Realty Income
8
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.5B
Madrigal Pharmaceuticals is involved in developing solutions for nonalcoholic steatohepatitis (NASH), a key area of focus for Inventiva.
Viking Therapeutics
VKTX
Mkt Cap4.07B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a competitor.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, competing with Inventiva's pipeline.
Agenus
AGEN
Mkt Cap370.88M
Agenus Inc. is focused on immuno-oncology but its interest in novel therapeutic approaches can indirectly compete with Inventiva's innovative treatments.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie has a diverse biopharmaceutical portfolio that includes research in fibrosis, making it a competitor.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a broad research portfolio that includes fibrosis and other areas relevant to Inventiva's interests.
Novartis
NVS
Mkt Cap304.1B
Novartis AG conducts extensive research in areas including fibrosis and metabolic diseases, overlapping with Inventiva's therapeutic areas.

About

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Show more...
CEO
Andrew Obenshain
Employees
77
Country
France
ISIN
FR0013233012
WKN
000A2DLV9

Listings

XETRA
DE
6IV.XETRA
STU
DE
6IV.STU
STU
DE
6IVA.STU
MU
DE
6IV.MU

0 Comments

Share your thoughts

FAQ

What is Inventiva stock price today?▼
The current price of 6IV.XETRA is €4.11 EUR — it has decreased by -0.48% in the past 24 hours. Watch Inventiva stock price performance more closely on the chart.
What is Inventiva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Inventiva stocks are traded under the ticker 6IV.XETRA.
What is Inventiva market cap?▼
Today Inventiva has the market capitalization of 969.74M
When is the next Inventiva earnings date?▼
Inventiva is going to release the next earnings report on September 27, 2026.
What were Inventiva earnings last quarter?▼
6IV.XETRA earnings for the last quarter are -0.94 EUR per share, whereas the estimation was -0.48 EUR resulting in a -97.22% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Inventiva revenue for the last year?▼
Inventiva revenue for the last year amounts to 4.48M EUR.
What is Inventiva net income for the last year?▼
6IV.XETRA net income for the last year is -354.14M EUR.
How many employees does Inventiva have?▼
As of September 07, 2026, the company has 77 employees.
In which sector is Inventiva located?▼
Inventiva operates in the Health & Wellness sector.
When did Inventiva complete a stock split?▼
Inventiva has not had any recent stock splits.
Where is Inventiva headquartered?▼
Inventiva is headquartered in Daix, France.